Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prostate-specific antigen kinetics and metastasis-free survival in patients treated with external beam radiotherapy combined with high-dose-rate brachytherapy boost and androgen deprivation therapy for localized prostate cancer.
Miszczyk M, Magrowski Ł, Masri O, Jabłon'ska I, Nowicka Z, Krzysztofiak T, Wojcieszek P, Lipka-Rajwa A, Ciepał J, Depowska G, Chimiak K, Bylica G, Płoszka K, Łaszczych M, Majewski W. Miszczyk M, et al. Among authors: magrowski l. J Contemp Brachytherapy. 2022 Feb;14(1):15-22. doi: 10.5114/jcb.2022.113546. Epub 2022 Feb 18. J Contemp Brachytherapy. 2022. PMID: 35233230 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 34701095
The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer.
Miszczyk M, Rembak-Szynkiewicz J, Magrowski Ł, Stawiski K, Namysł-Kaletka A, Napieralska A, Kraszkiewicz M, Woźniak G, Stąpór-Fudzińska M, Głowacki G, Pradere B, Laukhtina E, Rajwa P, Majewski W. Miszczyk M, et al. Among authors: magrowski l. Cancers (Basel). 2022 Mar 23;14(7):1613. doi: 10.3390/cancers14071613. Cancers (Basel). 2022. PMID: 35406385 Free PMC article.
Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost.
Moll M, Magrowski Ł, Mittlböck M, Heinzl H, Kirisits C, Ciepał J, Masri O, Heilemann G, Stando R, Krzysztofiak T, Depowska G, d'Amico A, Techmański T, Kozub A, Majewski W, Suwiński R, Wojcieszek P, Sadowski J, Widder J, Goldner G, Miszczyk M. Moll M, et al. Among authors: magrowski l. Strahlenther Onkol. 2024 Jun 3. doi: 10.1007/s00066-024-02245-3. Online ahead of print. Strahlenther Onkol. 2024. PMID: 38829436
Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients.
Miszczyk M, Magrowski Ł, Krzysztofiak T, Stando R, Majewski W, Stawiski K, Masri O, Ciepał J, Depowska G, Chimiak K, Bylica G, Czapla B, Masri M, Cichur F, Jabłońska I, Gmerek M, Nowicka Z, Wojcieszek P, Sadowski J, Suwiński R, Rajwa P, Goldner G, Moll M. Miszczyk M, et al. Among authors: magrowski l. Radiother Oncol. 2023 Jun;183:109632. doi: 10.1016/j.radonc.2023.109632. Epub 2023 Mar 23. Radiother Oncol. 2023. PMID: 36963442 Free article.
12 results